Teniposide in advanced breast cancer. A phase II trial in patients with no prior chemotherapy.
The objective response rates were determined using teniposide as first-line chemotherapy for patients with recurrent breast cancer. Twenty-seven evaluable patients with advanced disease received teniposide 70 mg/m2 i.v. days 1-5 every 3 weeks. A total of 211 courses were given. Responses included one complete (4%) and 9 partial responses (33%) with a median duration of response of 9 months (range 2-31 months). The main toxicity was myelosuppression. The results show that teniposide has at least modest activity in patients with advanced breast cancer treated previously with endocrine therapy.
Nielsen
D
D
Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark.
Boas
J
J
Engelholm
S A
SA
Hansen
O P
OP
Dombernowsky
P
P
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*
D013713:Teniposide